Comparison of Toxicities among Different Bumped Kinase Inhibitor Analogs for Treatment of Cryptosporidiosis

Recent advances on the development of bumped kinase inhibitors for treatment of cryptosporidiosis have focused on the 5-aminopyrazole-4-carboxamide scaffold, due to analogs that have less hERG inhibition, superior efficacy, and strong in vitro safety profiles. Three compounds, BKI-1770, -1841, and -...

Descripción completa

Detalles Bibliográficos
Autores principales: Hulverson, Matthew A., Choi, Ryan, Schaefer, Deborah A., Betzer, Dana P., McCloskey, Molly C., Whitman, Grant R., Huang, Wenlin, Lee, Sangun, Pranata, Andy, McLeod, Malcolm D., Marsh, Kennan C., Kempf, Dale J., LeRoy, Bruce E., Zafiratos, Mark T., Bielinski, Aimee L., Hackman, Robert C., Ojo, Kayode K., Arnold, Samuel L. M., Barrett, Lynn K., Tzipori, Saul, Riggs, Michael W., Fan, Erkang, Van Voorhis, Wesley C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112232/
https://www.ncbi.nlm.nih.gov/pubmed/36920244
http://dx.doi.org/10.1128/aac.01425-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10112232/
https://www.ncbi.nlm.nih.gov/pubmed/36920244
http://dx.doi.org/10.1128/aac.01425-22

Ejemplares similares